Institute of Genetic Medicine

Cancer Genomics

Cancer Genomics

The Institute of Genetic Medicine has state-of-the-art facilities to investigate cancer at the genomic, transcriptomic and cell biological levels.

Our resources include the region’s only single cell sequencing facility that couples single cell capture with next generation sequencing technologies.

Our clinical research includes investigation of tumour predisposition syndromes as a model to discover oncogenic dependencies and deliver interventional clinical trials for patient benefit. A landmark study reflecting this is CAPP3, where aspirin has been highlighted as a chemoprevention strategy in families with colorectal cancer predisposition due to mutations in DNA mismatch repair genes. Bioinformatic analysis of data from rare cancers has also led to the development of novel diagnostic tests in mismatch repair. We partner with rare disease patients to carry out pioneering early phase interventional trials, such as the TRAC study in CYLD cutaneous syndrome, as well as run a rare disease public engagement programme.

Our basic science cancer genomic research investigates cancer stem cells, kidney cancer, RNA splicing biology controls in prostate and breast cancer, the functions of microRNAs in breast cancer, and the biology of sugar modifications of both protein and lipids in prostate cancer. Clinical outputs from these research areas are instrumental to gain novel insights for prognostic and therapeutic benefit for patients.